Preclinical evaluation of a next-generation, subcutaneously administered, coagulation factor IX variant, dalcinonacog alfa.

Preclinical evaluation of a next-generation, subcutaneously administered, coagulation factor IX variant, dalcinonacog alfa.

<h4>Introduction</h4>The rapid clearance of factor IX necessitates frequent intravenous administrations to achieve effective prophylaxis for patients with hemophilia B. Subcutaneous administration has historically been limited by low bioavailability and potency. Dalcinonacog alfa was dev...

Full description

Bibliographic Details
Main Authors: Timothy C Nichols, Howard Levy, Elizabeth P Merricks, Robin A Raymer, Martin L Lee
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0240896

Internet

https://doi.org/10.1371/journal.pone.0240896

Similar Items